New Combo Therapy Extends Survival By More Than A Year In Advanced Triple Positive Breast Cancers By Dennis Thompson HealthDay ReporterWEDNESDAY, Feb. 4, 2026 (HealthDay News) — Taking one additional ...

Watch me create the perfect lip combo with dark brown lip liner and a pink lipstick for a bold and beautiful look, perfect for black girls #makeupforblackgirls #darkbrownlipliner #lipcombotutorial ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Abstract: Resource allocation and link adaptation in Long-Term Evolution (LTE) and LTE Advanced are discussed with focus on the location and formatting of the pertinent reference and control signals, ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...

A new mix of two drugs—enzalutamide and leuprolide—has been shown to lower the risk of death by 40.3% for men with advanced, returning prostate cancer. This study with nearly eight years of follow-up, ...

"Achieving breakthrough results in production at high volume is a significant milestone for Silicon Box, as well as for transitioning the industry towards more scalable and low-cost design and ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...